Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Straub CE marks endovascular catheters for further indications

This article was originally published in Clinica

Executive Summary

Straub Medical has CE marked its new-generation Rotarex S and Aspirex S families of rotational endovascular catheters for additional indications and subsequently upgraded the classification of the devices from Class II to III. The catheters, in combination with the Straub Medical Drive System, can now be marketed for the percutaneous transluminal removal of material from occlusions of all blood vessels outside the cardiopulmonary, coronary and cerebral circulations. Both catheters may be used in native blood vessels or vessels fitted with stents, stent grafts or native or artificial bypasses. Aspirex S catheters are intended to be used for the removal of fresh thrombotic or thromboembolic material, and Rotarex S catheters are designed to remove thrombotic, thromboembolic and atherothrombotic material from fresh, subacute and chronic occlusions. The Wangs, Switzerland company initially CE marked the devices in 1999.

You may also be interested in...

Five minutes with… Noam Emanuel of PolyPid

Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.

Mesoblast's blood cancers stem cell therapy moves closer to market

Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.

Mesoblast stem cell therapy advances into Phase II for spinal degeneration

Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts